Balloon-Assisted Thrombectomy and Intrasinus Urokinase Thrombolysis for Severe Cerebral Venous Sinus Thrombosis.

Jiansheng Yang,Hongyang Wang,Yanxing Chen,Zhicai Chen,Minjian Qiu,Baorong Zhang

doi:10.3389/fneur.2021.735540

Abstract

Background: Current clinical guidelines recommend systemic anticoagulation as the initial treatment for severe cerebral venous sinus thrombosis (CVST). However, anticoagulation alone does not always dissolve large and extensive CVSTs in some patients. Here, we investigated the effectiveness and safety of balloon-assisted thrombectomy and intrasinus urokinase thrombolysis in our retrospective study of a series of 23 patients with CVST.Methods: We reviewed the clinical, radiological, and outcome data of all patients. Complete recanalization was defined as all the occluded sinuses were recanalized on digital subtraction angiography or Contrast-enhanced magnetic resonance venography. Partial recanalization was defined as the complete recanalization of one sinus but persistent occlusion of other sinuses, or partial recanalization of one or more sinuses. The modified Rankin Scale (mRS) was used to represent the clinical outcome.Results: From May 2017 to November 2019, a total of 23 patients were treated with balloon-assisted thrombectomy and intrasinus urokinase thrombolysis. A total of 84 venous sinuses were involved, ≥3 sinuses were involved in 20 (87%) patients. Among them, 21 (91%) patients achieved technical success. Complete and partial recanalization were obtained in 17 (81%) and 4 (19%) patients at 6 months follow-up, respectively. All 21 patients had mRS scores of 0 (18) or 1 (3).Conclusions: Our case series shows that balloon-assisted thrombectomy combined with intrasinus urokinase thrombolysis and activated partial thromboplastin time-regulated systemic anticoagulation is safe and effective in treating severe CVST.

Highlights

Cerebral venous sinus thrombosis is an infrequent cause of stroke, accounting for 0.5–1% of all strokes
Patients with cerebral venous sinus thrombosis (CVST) treated with balloon-assisted thrombectomy and intrasinus urokinase thrombolysis in our center were identified between May 2017 and November 2019
From May 2017 to November 2019, a total of 23 patients were treated with balloon-assisted thrombectomy and intrasinus

Summary

Introduction

Cerebral venous sinus thrombosis is an infrequent cause of stroke, accounting for 0.5–1% of all strokes. Based on the results of some randomized controlled studies, current clinical guidelines recommend systemic anticoagulation as the initial treatment for cerebral venous sinus thrombosis (CVST) [1, 2]. In CVST patients with complete occlusion in multiple sinuses, the effect of heparin is decreased because the drug cannot fully penetrate into the thrombus [9,10,11]. According to the results of the International Study on Cerebral Vein and Dural Sinus Thrombosis, at least 13% of all patients with CVST die or remain severely handicapped [3]. Current clinical guidelines recommend systemic anticoagulation as the initial treatment for severe cerebral venous sinus thrombosis (CVST). Anticoagulation alone does not always dissolve large and extensive CVSTs in some patients. We investigated the effectiveness and safety of balloon-assisted thrombectomy and intrasinus urokinase thrombolysis in our retrospective study of a series of 23 patients with CVST

Methods

Results

Conclusion